ReviewBiomaterials2019
Microfluidic devices for disease modeling in muscle tissue.
Review in Biomaterials, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
10 citing papers in PubMed, 21 citations in OpenAlex.
- Classification system proposed to guide the design, development, regulatory approval, and scaling of long acting, small- and macro-molecule parenteral products (CS-BLAP).Journal of pharmaceutical sciences · 2026Review
- Shear-Stress Initiates Signal Two of NLRP3 Inflammasome Activation in LPS-Primed Macrophages through Piezo1.ACS applied materials & interfaces · 2025Article
- Leveraging Biomaterial Platforms to Study Aging-Related Neural and Muscular Degeneration.Biomolecules · 2024Review
- Type 2 diabetes mellitus as a possible risk factor for myasthenia gravis: a case-control study.Frontiers in neurology · 2023Article
- The importance of intermediate filaments in the shape maintenance of myoblast model tissues.eLife · 2022Article
- Three-Dimensional In Vitro Cell Culture Models for Efficient Drug Discovery: Progress So Far and Future Prospects.Pharmaceuticals (Basel, Switzerland) · 2022Review
- Cell-Based Microfluidic Device Utilizing Cell Sheet Technology.Cyborg and bionic systems (Washington, D.C.) · 2022Article
- Computational and experimental studies of a cell-imprinted-based integrated microfluidic device for biomedical applications.Scientific reports · 2021Article
- Bioinspired electrospun dECM scaffolds guide cell growth and control the formation of myotubes.Science advances · 2021Article
- Fabrication and Characterization of Electrospun Decellularized Muscle-Derived Scaffolds.Tissue engineering. Part C, Methods · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
Abstract
Microfluidic devices have advanced significantly in recent years and are a promising technology for the field of tissue engineering. Highly sophisticated microfabrication techniques have paved the way for the development of complex ex vivo models capable of incorporating and measuring the real-time response of multiple cell types interacting together in a single system. Muscle-on-a-chip technology has drastically improved and serves as a drug screening platform for many muscular diseases such as muscular dystrophy, tendinosis, fibromyalgia, mitochondrial myopathy, and myasthenia gravis. This review seeks to communicate the gaps in knowledge of current muscular disease models and highlight the power of microfluidic devices in enabling researchers to better understand disease pathology and provide high throughput screening of therapeutics for muscular myopathies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.